Growth-hormone secretagogues are a popular area of peptide research because they work with the body’s own signaling rather than introducing growth hormone directly. Two of the most-studied options are Sermorelin and the CJC-1295 + Ipamorelin combination. This comparison is for educational reference only.
Two mechanisms
| Compound | Class | Mechanism studied |
|---|---|---|
| Sermorelin | GHRH analog (1-29) | Stimulates GHRH receptors |
| CJC-1295 (no DAC) | GHRH analog | Stimulates GHRH receptors, longer-acting |
| Ipamorelin | GHRP / ghrelin-receptor agonist | Selective GH secretagogue via a separate receptor |
Sermorelin
Sermorelin is a GHRH(1-29) analog — the shortest fragment that retains GHRH activity. It is studied as a straightforward model of GHRH-receptor stimulation. Explore Sermorelin.
CJC-1295 + Ipamorelin
This research blend pairs a GHRH analog (CJC-1295 no DAC) with a selective secretagogue (Ipamorelin) that acts on the ghrelin receptor. Because the two act on different receptors, they are frequently studied together in pulsatile-secretion models. Explore the CJC-1295 + Ipamorelin blend.
How researchers choose
The choice typically depends on whether a study is examining a single GHRH pathway (Sermorelin) or the combined effect of GHRH plus a secretagogue acting on a second receptor (CJC-1295 + Ipamorelin). Tesamorelin is another GHRH analog used in this space.
Handling and quality
All are reconstituted with bacteriostatic water. Always confirm identity and purity via a batch-specific Certificate of Analysis.
For laboratory and research use only. Not for human or animal consumption. This article summarizes publicly available research and is not medical advice.